<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10874">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619112</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000572434</org_study_id>
    <secondary_id>UCSF-H44867-31182-01</secondary_id>
    <secondary_id>UCSF-07107</secondary_id>
    <secondary_id>SPRI-UCSF-H44867-31182-01</secondary_id>
    <nct_id>NCT00619112</nct_id>
    <nct_alias>NCT00539552</nct_alias>
  </id_info>
  <brief_title>Temozolomide in Treating Patients With Recurrent High-Grade Glioma</brief_title>
  <official_title>Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.

      PURPOSE: This phase II trial is studying how well temozolomide works in treating patients
      with recurrent high-grade glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the efficacy, as measured by 6-month progression-free survival, of a
           dose-intense temozolomide treatment schedule in patients with recurrent high-grade
           glioma.

      Secondary

        -  Assess the toxicities of this dose-intense temozolomide.

        -  Determine the overall survival of patients treated with this dose-intense schedule.

        -  Determine whether methylation status of the MGMT gene within patients' tumors predicts
           greater efficacy (progression-free survival), in patients treated on this protocol.

        -  Determine whether patients' tumors have functional alterations of the mismatch repair
           (MMR) system by PCR analysis for microsatellite instability (MSI) and whether such
           alterations may influence outcome in patients treated on this protocol.

        -  Determine how initial success with temozolomide may influence outcome in recurrent
           patients treated on this protocol by evaluating patients progressing after two
           first-line adjuvant courses of temozolomide, patients progressing within 6 months after
           the 6th adjuvant course of temozolomide, and patients progressing 6 months after
           temozolomide is voluntarily discontinued.

      OUTLINE: Patients receive oral temozolomide once daily on days 1-7 and days 15-21. Treatment
      repeats every 28 days for up to 12 courses in the absence of disease progression or
      unacceptable toxicity.

      Formalin-fixed paraffin-embedded tissue blocks or unstained paraffin slides from available
      surgical samples are evaluated for molecular abnormalities in the tumor, including (but not
      limited to) MGMT status and microsatellite instability.

      After completion of study therapy, patients are followed every 3 months for survival.

      PROJECTED ACCRUAL: A total of 40 patients with WHO II grade 4 tumors (glioblastoma
      multiforme [GBM]) and 20 patients with WHO II grade 3 tumors (non-GBM) will be accrued for
      this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy, as Measured by 6-month Progression-free Survival, of the Dose-intense Temozolomide Treatment Schedule; This Endpoint Was Measured From the First Day of Treatment Until Progression or 6month Mark From Treatment Initiation.</measure>
    <time_frame>Study start was 10.31.2007. Enrollment was completed on 12/22/2011</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity Associated With the Dose-intense Temozolomide Treatment Schedule as Assessed by NCI CTCAE v3.0</measure>
    <time_frame>Study start was 10.31.2007. Enrollment was completed on 12/22/2011</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Recurrent Central Nervous System Neoplasm</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm trial; Patients treated with temozolomide at a dose of 150mg/m2 daily for seven consecutive days of every other week. One 28-day cycle will include treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>single arm study</description>
    <arm_group_label>Temozolomide</arm_group_label>
    <other_name>temodar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients with radiographically proven recurrent, intracranial malignant glioma will
             be eligible for this protocol.

          -  All patients must sign an informed consent

          -  Patients must have had external beam radiation; there is no limit to the number of
             prior chemotherapies used.

          -  Patients must be &gt; 18 years old, and with a life expectancy &gt; 8 weeks.

          -  Patients must have a Karnofsky performance status of &gt; 60.

          -  At the time of registration: Patients must have recovered from the toxic effects of
             prior therapy:

          -  Patients must have adequate bone marrow function.

          -  Patients must have shown unequivocal radiographic evidence for tumor progression by
             MRI

          -  Patients having undergone recent resection of recurrent or progressive tumor will be
             eligible as long as all of the following conditions apply: They have recovered from
             the effects of surgery. Residual disease following resection of recurrent
             intracranial malignant glioma is not mandated for eligibility into the study.

          -  Patients must have failed prior radiation therapy and must have an interval of
             greater than or equal to 42 days from the completion of radiation therapy to study
             entry.

          -  Patients with prior therapy that included interstitial brachytherapy, stereotactic
             radiosurgery, or Gliadel wafers must have confirmation of true progressive disease
             rather than radiation necrosis based upon either PET or MR spectroscopy or surgical
             documentation of disease.

          -  Male and female patients with reproductive potential must use an approved
             contraceptive method

        Exclusion Criteria

          -  Patients must not have any significant medical illnesses that in the investigator's
             opinion cannot be adequately controlled with appropriate therapy or would compromise
             the patient's ability to tolerate this therapy

          -  Patients with a history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
             for that disease for a minimum of 3 years are ineligible.

          -  Patients must not have active infection or serious intercurrent medical illness.

          -  Patients must not be pregnant/breast feeding and must agree to practice adequate
             contraception.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas A. Butowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan M. Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 29, 2013</lastchanged_date>
  <firstreceived_date>February 19, 2008</firstreceived_date>
  <firstreceived_results_date>June 17, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from within established neuro oncology clinic at UCSF. First paient 11.5.2007 and last patient 1.24.2012</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Temozolomide</title>
          <description>single arm trial
temozolomide : single arm study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60">enrolled all patients from Nov 2007 to Jan 2012</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temozolomide</title>
          <description>single arm trial
temozolomide : single arm study</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60" spread=".01"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy, as Measured by 6-month Progression-free Survival, of the Dose-intense Temozolomide Treatment Schedule; This Endpoint Was Measured From the First Day of Treatment Until Progression or 6month Mark From Treatment Initiation.</title>
        <time_frame>Study start was 10.31.2007. Enrollment was completed on 12/22/2011</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>single arm trial
temozolomide : single arm study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of MRI of brain analyzed</title>
            <units>MRI of brain</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Efficacy, as Measured by 6-month Progression-free Survival, of the Dose-intense Temozolomide Treatment Schedule; This Endpoint Was Measured From the First Day of Treatment Until Progression or 6month Mark From Treatment Initiation.</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Associated With the Dose-intense Temozolomide Treatment Schedule as Assessed by NCI CTCAE v3.0</title>
        <time_frame>Study start was 10.31.2007. Enrollment was completed on 12/22/2011</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Temozolomide</title>
          <description>single arm trial
temozolomide : single arm study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>low platetles due to temozolmide</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>lymphopenia</sub_title>
                <description>low wbc related to prior and current chemo</description>
                <counts group_id="E1" events="40" subjects_affected="20" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <description>low neutrophls</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <description>fatigue, unrelated to study drug</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>confusion</sub_title>
                <description>confusion, unrelated to study drug</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>neuropathy motor</sub_title>
                <description>weakness due to disease</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial reached enrollment. There were no unexpected toxicities.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nicholas Butowski</name_or_title>
      <organization>UCSF</organization>
      <phone>4153532966</phone>
      <email>Butowski@neurosurg.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
